Cancer is the second leading cause of death in the United States. Around the globe, cancer incidence has been steadily increasing over the past half-century. Read article in The Jerusalem Post here.

The question I have asked myself and many others most often over the pa...

Dear Colleagues and Friends,

Our fourth Alpha Tau Newsletter is full of fantastic updates that I am very excited to share with you.
 
I am thrilled to inform you that our first clinical trial results have been published! The exceptional results were presented in the I...

Alpha DaRT™ achieves a 78.6% complete response rate in management of challenging squamous cell carcinoma tumors.

Tel Aviv, Israel, November 26, 2019 – Alpha Tau Medical is pleased to announce the publication of the results of its first clinical trial of Alpha DaRT™, a...

October 7 is the birth date of Danish physicist Niels Bohr [1] (1885-1862). Bohr has a special significance for Alpha Tau, for two reasons. The first reason is because he was one of the key contributors to the foundational discoveries in atomic physics at the beginning...

"It is my honor to assume the duty of Chief Scientific Officer of ATM," said Prof. Keisari, "our alpha radiation-based brachytherapy has already demonstrated its potential to treat tumorous lesions in humans, and I see it as my mission to take this treat...

Alpha Tau Medical, developer of the breakthrough alpha radiation cancer therapy Alpha DaRT, announced today the appointment of Dr. Robert B. Den, MD, as Chief Medical Officer (CMO). In his new role, and as a prominent expert and accomplished clinician, Dr. Den will lea...

Dear Colleagues and Friends, 

I am thrilled to share with you our newest developments achieved in the past months - whether it comes to new collaborations, approvals, research or operational developments, Alpha Tau is rapidly progressing!

In the last several weeks, we ha...

We're excited that at this year’s American Brachytherapy Society (ABS) Meeting, Prof. Keisari was awarded the Best Oral Presentation Award at the Breast Plenary Session!

Prof. Keisari presented his results on “Immunomodulation of the Antitumor Response Induced by Alpha...

Alpha Tau Medical, developer of the breakthrough alpha radiation cancer therapy, Alpha DaRT, announced today that it has obtained ISO 13485:2016 certification. The certification was awarded following an audit by the UK's independent national compliance body, British St...

Tel Aviv, Israel, March 26, 2019 – Alpha Tau Medical, developer of the breakthrough alpha radiation cancer therapy, Alpha DaRT, announced today that Mr. Raphi Levy will be joining Alpha Tau’s management team as Chief Financial Officer. Mr. Levy will focus primarily on...